SP

Stephen Parker

Dr Parker has over 31 years of experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a venture capitalist and a senior corporate financier with Baring's, Warburg's and Apax Partners.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
MXC
MXC
30/06/23600,0001,393,427N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
MXC
MXC
05/05/23
Expiry
1,400,000$0.009$12,600As advised by the company
RGT
RGT
05/05/23
Expiry
1,400,000$0.009$12,600As advised by the company
MXC
MXC
06/05/22
Buy
1,111,111$0.014$15,011On-market trade
MXC
MXC
07/10/21
Exercise
600,000$0.059$35,400Conversion of securities
MXC
MXC
07/10/21
Buy
600,000$0.059$35,400Conversion of securities